Evaluation of ovarian function and metabolic factors in women affected by polycystic ovary syndrome after treatment with d-Chiro-Inositol

Abstract

D-Chiro-Inositol is effective in improving ovarian function and metabolism of patients affected by PCOS.

Authors’ reply to: “Empiric” inositol supplementation in normal-weight non-insulin resistant women with polycystic ovarian disease: from the absence of benefit to the potential adverse effects

“…In our previous study [1], even if all the recruited patients were lean, we reported 5.38 ± 1.54 as mean glycaemia/IRI ratio and 3.44 ± 1.18 as mean HOMA (Homeostasis Model Assessment) index, so we evidenced insulin resistance/hyperglycaemia (HOMA C 2.5) in the enrolled population. Moreover, none of these patients had diabetic relatives (first or second degree).…”

“…We appreciate Vitagliano and Colleagues' interest in our recent article [1] about ovarian function and metabolic factors in women affected by polycystic ovary syndrome (PCOS) after treatment with D-chiro-inositol. We are grateful for their insightful comments [2] and the opportunity to clarify a number of elements from our work.…”

The “Other” Inositols and Their Phosphates: Synthesis, Biology, and Medicine (with Recent Advances inmyo‐Inositol Chemistry)

“…[132] The treatment of 48 patients affected by PCOS and menstrual irregularities with D-chiro-inositol and folic acid resulted in statistically significant improvements in several measures of ovarian function and metabolic function. [133] In PCOS sufferers metformin increases the insulin-stimulated release of the putative D-chiroinositol-containing phosphoglycan that mediates insulin action: [134] there is a selective impairment in PCOS sufferers between insulin action and the release of the mediator. [135] PCOS has been associated with a degree of oxidative stress: the administration of D-chiroinositol to PCOS sufferers prevents the oxidation of protein thiol groups in the follicular fluid.…”

Nutrients as novel therapeutic approaches for metabolic disturbances in polycystic ovary syndrome

“…1) (References in Table 1: Costantino et al, 2009[13]; Genazzani et al, 2014[27]; Genazzani et al, 2008[25]; Nestler et al, 1999[48]; Genazzani et al, 2014[26]; Laganà et al, 2015[39]; Nordio and Proietti, 2012[49]; Pizzo et al, 2014[60]).…”